Back to Stakeholders
Research, Drug Development & ManufacturingAcademic & Non-Profit Research
Research, Drug Development & ManufacturingAcademic & Non-Profit ResearchUniversities and Colleges with Dedicated Psychedelic Research Groups
Research, Drug Development & Manufacturing

University of Washington

United States
5 Trials2 Papers

At UW, researchers are working on clinical trials with psilocybin (provided by Usona). Dr Anthony Back, co-director of the University's Center for Excellence in Palliative Care, led a trial exploring the effects of psilocybin to alleviate the mental health burden inflicted on frontline healthcare workers throughout the COVID-19 pandemic. As Seattle became the largest city in the US to decriminalise psilocybin mushrooms in October 2021, and with ongoing legislative efforts at the state level, more research with psychedelics is anticipated and occurring at UW.

Academic Research

2 papers

Published Papers

2

Trial Involvement

5

Distinct Focus Topics

0

Latest Publication

Jan 18, 2026

Quick Facts

Type
academic
HQ
United States
Website
Visit

Sponsored Trials

5
Not yet recruitingII

Group Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or Incurable Hematologic Malignancies

Start Date
Compounds
Psilocybin
CompletedI

A Second Psilocybin Group Therapy for the Treatment of Cancer-Related Anxiety in Partial Responders With Metastatic Cancer

Start Date
Compounds
Psilocybin
Active not recruitingI

MDMA-Assisted Therapy for Pathological Narcissism

Start Date
Compounds
MDMA
CompletedI, II

Psilocybin-Assisted Therapy for the Treatment of Cancer-Related Anxiety in Patients With Metastatic Cancer

Start Date
Compounds
Psilocybin
CompletedIII

Frontline Clinician Psilocybin Study

Start Date
Compounds
Psilocybin, Placebo

Research Papers

2
Open Accessindividual

Group Retreat Psilocybin Therapy for People with Metastatic Cancer with Symptoms of Anxiety and Depression: Safety and Efficacy Outcomes of a Phase 1/2 Study

This Phase I/II study (n=52) tested a group retreat model of psilocybin therapy for people with metastatic cancer and anxiety or depression, using 25 mg psilocybin in a 3-day retreat format. No unattended distress episodes occurred, and anxiety and depression scores fell over 28 days.

Published
Journal
Psychedelic Medicine
Authors
Back, A. L., McGregor, B. A., Thorn, L. L., Baker, K., Gooley, T., Kaelen, M., Harvey, K., Guy, J. M., Myers, S., Perez, J., Thompson, P., Billingsley, L., Sesnon, C.
Paywallindividual

Group Retreat Psilocybin Therapy for People with Metastatic Cancer with Anxiety and Depression: A Rite of Passage Facilitation Model for a Phase 1/2 Study

This secondary analysis (n=52) describes a Phase I/II group psilocybin retreat model for people with metastatic cancer and moderate to severe anxiety or depression, using a secular ritual approach based on rites of passage. It describes a model designed for a 3-day in-person retreat and linked to safety and efficacy outcomes in the trial.

Published
Journal
Psychedelic Medicine
Authors
Back, A. L., McGregor, B. A., Billingsley, L., Blom, D., Callan, G., Myers, S., Guy, J., Kumar, S., Layer, M., Levin, J., Perez, J., Thompson, P., Salmonson, K., Whinney, J., Thorn, L. L.